BRIACELL THERAP BCTX

DSMB recommends continuing BriaCell’s Phase 3 metastatic breast cancer study. DSMB continuation advances BriaCell Phase 3 trial toward potential approval.

BriaCell expands pivotal Phase 3 metastatic breast cancer study to leading cancer center. Phase 3 trial expansion to major center speeds enrollment and strengthens development path for BriaCell's breast cancer therapy.

BriaCell shares turned volatile after reaching a melanoma vaccine development milestone. Melanoma vaccine milestone represents major strategic progress that can significantly alter BriaCell trajectory and investor sentiment.

BriaCell advances personalized melanoma immunotherapy vaccine candidate Bria-MEL+™. Advancement of core Bria-MEL+™ candidate marks major pipeline progress for BriaCell with potential to shift competitive trajectory.

BriaCell receives FDA clearance to initiate Bria-PROS+ clinical study in prostate cancer. FDA clearance for new prostate cancer trial expands pipeline and market opportunity.

CRA International assumes new role with Bria-IMT, potentially strengthening its healthcare competitive advantage and pricing power with direct implications for BriaCell Therapeutics (BCTX). CRA International's new Bria-IMT role signals a strategic collaboration that could moderately boost BCTX positioning without guaranteed fundamental change.

BriaCell opens first Canadian site at Sunnybrook for pivotal Phase 3 trial in metastatic breast cancer. Phase 3 site launch advances BriaCell's lead program toward potential approval and commercialization.

BriaCell arranges scalable manufacturing agreement with FUJIFILM Biotechnologies for Bria-IMT™. Manufacturing deal supports Bria-IMT production scaling and operational readiness.

BriaCell engages consulting and branding firms to evaluate commercial strategy and market access for Bria-IMT™. Hiring firms for Bria-IMT market evaluation advances commercialization planning.

BriaCell partners with Uneedle to develop scalable microneedle technology for Bria-IMT administration. Partnership advances delivery method for core Bria-IMT product.

BriaCell Therapeutics closed an offering. Closing an offering supplies BriaCell Therapeutics with fresh capital that supports operations and may lift near-term sentiment.

BriaCell presents final Phase 2 and ongoing Phase 3 clinical data at ASCO meeting. Clinical data presentations at ASCO can drive major shifts in company valuation and investor outlook.

BriaCell presented positive clinical data at ASCO 2026. Positive clinical data at ASCO signals major progress for BriaCell's pipeline and market positioning.

BriaCell receives positive DSMB recommendation for Phase 3 study in metastatic breast cancer. Positive DSMB review advances Phase 3 trial for BriaCell's lead metastatic breast cancer candidate.

BriaCell presented positive clinical data for Bria-IMT™ at ASCO 2026. Positive clinical data at major oncology conference drives substantial investor interest and potential valuation gains.

BriaCell Therapeutics expands its clinical pipeline to include Bria-OVA+, an off-the-shelf immunotherapy candidate targeting ovarian cancer, building on its personalized breast cancer therapies. Pipeline expansion into ovarian cancer with a new immunotherapy candidate diversifies therapeutic focus and boosts long-term growth potential.

BriaCell Therapeutics completes manufacturing of clinical supplies for Bria-PROS+, its next-generation immunotherapy candidate, advancing toward clinical trials. Manufacturing completion de-risks clinical advancement for Bria-PROS+, enabling trials that could significantly enhance BriaCell's pipeline and investor confidence.

BriaCell completed manufacturing of clinical supplies of Bria-PROS+™, its investigational prostate cancer immunotherapy, advancing toward clinical trials. Completing clinical supply manufacturing marks a major milestone in BriaCell's prostate cancer pipeline development, likely boosting investor sentiment and stock performance.

BriaCell Therapeutics adds Penn Medicine’s Abramson Cancer Center as a new clinical site in its pivotal Phase 3 breast cancer study. Adding a top cancer center to the pivotal Phase 3 trial accelerates enrollment, enhances credibility, and advances path to potential approval.

BriaCell Therapeutics' Phase 3 Bria-IMT™ study enrollment surpasses 230 patients, advancing the trial for their lead immunotherapy candidate in metastatic breast cancer. Surpassing 230 patients in Phase 3 enrollment accelerates BriaCell's path to potential FDA approval and enhances market sentiment.

BriaCell Therapeutics adds NYU Langone Health’s Perlmutter Cancer Center as a new clinical site in its pivotal Phase 3 breast cancer study. Adding a top-tier cancer center to the pivotal Phase 3 trial boosts enrollment speed, credibility, and investor sentiment for BriaCell's lead breast cancer therapy.

BriaCell Therapeutics (BCTX) received FDA clearance to initiate its Phase 1/2a clinical study for Bria-BRES+, an off-the-shelf cell therapy targeting breast cancer patients who failed prior treatments. FDA clearance for Phase 1/2a Bria-BRES+ study represents a major regulatory milestone advancing BriaCell's breast cancer pipeline and likely boosting investor sentiment.

BriaCell Therapeutics (BCTX) received FDA clearance to initiate the Bria-BRES+™ clinical study targeting breast cancer patients. FDA clearance for Bria-BRES+™ study initiation represents a major regulatory milestone advancing BriaCell's breast cancer immunotherapy pipeline and likely boosting investor sentiment.

BriaCell Therapeutics (BCTX) announces six clinical data presentations at ASCO 2026, covering advances in personalized immunotherapies including Bria-IMT for breast cancer, Bria-BRST for advanced breast cancer, and combination therapies. Six presentations at the premier ASCO 2026 oncology conference underscore robust clinical progress, likely driving significant investor enthusiasm and stock gains.

BriaCell demonstrates robust anti-cancer activity of Bria-OTS+ in preclinical cancer models. Robust preclinical results for Bria-OTS+ advance BriaCell's oncology pipeline, moderately boosting investor sentiment and development prospects.

BriaCell presented positive Phase 3 quality of life data and Phase 2 biomarker data at the 2026 AACR Meeting. Positive Phase 3 quality of life and Phase 2 biomarker data at AACR signals pipeline advancement, boosting investor sentiment and market performance for the biotech.

BriaCell and BriaPro closed an asset purchase transaction granting BriaCell an exclusive worldwide license to soluble CD80 (sCD80) technology, enhancing its immunotherapy portfolio for cancer treatment. Securing an exclusive license to soluble CD80 technology represents a major strategic asset acquisition that strengthens BriaCell's oncology pipeline and competitive edge.

BriaCell to present positive clinical data for Bria-IMT™ and preclinical data for next-generation Bria-OTS+™ personalized immunotherapy at the 2026 AACR Conference. Positive clinical data presentation at AACR highlights pipeline progress in cancer immunotherapy, likely driving significant investor sentiment and valuation uplift.

BriaCell Therapeutics (BCTX) to present four poster presentations at the 2026 AACR Annual Meeting. Multiple poster presentations at AACR highlight advancing cancer research pipeline and enhance scientific credibility.

BriaCell Therapeutics and BriaPro Immunotherapeutics entered an asset purchase agreement granting BriaPro exclusive worldwide rights to develop, manufacture, and commercialize BriaCell's soluble CD80 (sCD80) fusion protein technology. BriaCell receives an upfront payment, milestone payments up to $93 million, and royalties on net sales. The deal streamlines BriaCell's operations to focus on its lead TC-1 cancer vaccine program. Exclusive licensing of sCD80 provides non-dilutive funding via upfront cash, milestones, and royalties while refocusing resources on the core TC-1 program.